FEops

What FEops does

FEops is a Gent, Belgium-based digital health company founded in 2009 that develops AI-enabled predictive simulation software for structural heart interventions. Its core product, FEops HEARTguide, is a cloud-based SaaS platform that ingests cardiac CT scans, applies AI-based anatomical measurements to identify and quantify cardiac landmarks, and runs patient-specific finite element simulations to predict how transcatheter devices will interact with a given patient's anatomy. The platform supports three clinical workflows: left atrial appendage occlusion (LAAO) planning, transcatheter aortic valve implantation (TAVI) planning with lifetime management features, and transcatheter mitral valve replacement (TMVR) neo-LVOT assessment (research stage). Predictive outputs include device apposition, frame deformation, compression rate, paravalvular leak risk, and conduction disturbance risk, with the platform covering devices from Medtronic, Boston Scientific, Abbott, and Venus Medtech.

The company operates a two-segment business model. The primary segment is a healthcare professional subscription offering, sold to hospitals and structural heart programs via direct enterprise field sales across Europe, the UK, Switzerland, Canada, Australia, and the US; the platform is deployed at 466 hospitals across 38 countries with 11,461 patients modeled. The second segment provides finite element analysis and fatigue assessment professional services to cardiovascular medical device manufacturers, supporting R&D and first-in-human studies (e.g., TRiCares Topaz TTVR). Regulatory positioning includes CE mark for TAVI (2015) and LAAO (2019), FDA authorization for LAAO planning (2021/2022), and FDA clearance for AI-based anatomical analysis (2023), with a 510(k) pending for TAVI Lifetime Management. Clinical validation is anchored in the PREDICT-LAA, PRECISE-TAVI, and PRECISE-LAA trials.

In July 2024, FEops was acquired by Materialise (NASDAQ: MTLS), a global 3D printing software and services company, and now operates as a wholly-owned subsidiary integrated with Materialise's Mimics Planner cardiovascular planning solution. Founders Matthieu De Beule (CEO) and Peter Mortier (CTO) continue to lead the business. Total disclosed funding prior to acquisition was approximately EUR 13.8M across a Series A (EUR 1.3M, 2015), Series B (EUR 6M, 2017, led by Valiance), an EIC Horizon 2020 grant (EUR 3.2M, 2019), and an EIC convertible loan (EUR 3.3M, 2022).

Name

FEops

Legal name

FEops NV

Website

https://feops.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

FEops, a Gent, Belgium-based digital health company (now a Materialise subsidiary), provides the cloud-based FEops HEARTguide SaaS platform that uses AI-based anatomical measurements and patient-specific predictive simulation to plan transcatheter structural heart procedures for hospitals and cardiovascular device manufacturers.

Ownership category

akta.pro rank

Product category

Cardiovascular Procedure Planning Software

NAICS

Computer Systems Design and Related Services (5415), Other Scientific and Technical Consulting Services (54169)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

akta.pro secondary industry

Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG) (HLAGAAAJ)

Keywords

• Structural heart planning
• Cardiovascular simulation software
• TAVI procedure planning
• LAAO procedure planning
• Medical imaging AI

Headquarters

HQ city

Gent

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Healthcare Professional Subscriptions: Cloud-based SaaS platform providing AI-enabled anatomical analysis and predictive simulation for structural heart procedure planning. Healthcare professionals and hospitals subscribe to access the FEops HEARTguide platform for patient case analysis.
2. Medtech Device Company Services: FEops provides simulation services to cardiovascular device companies for R&D, design optimization, fatigue assessment, and first-in-human study support. Services include deployment simulation, cyclic loading analysis, and device performance prediction.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

FEops offers FEops HEARTguide, a cloud-based structural heart procedure planning platform that combines predictive simulation technology with AI-based anatomical measurements to analyze cardiac CT scans. The platform enables interventional cardiologists and cardiac surgeons to predict how transcatheter structural heart devices (TAVI valves and LAAO occluders) will interact with patient-specific anatomy before procedures, supporting pre-procedural device sizing, positioning, and complication risk assessment. The company also provides Finite Element Analysis (FEA) simulation services to cardiovascular medical device manufacturers for R&D, design optimization, fatigue assessment, and first-in-human study support.

Product overview

FEops is a digital health company offering FEops HEARTguide, a cloud-based structural heart procedure planning platform that combines AI-based anatomical analysis with predictive simulation technology. The platform consists of multiple clinical workflows including LAAO Workflow for left atrial appendage occlusion planning, TAVI Workflow for transcatheter aortic valve implantation with lifetime management features, and TMVR Workflow for mitral valve replacement research. The platform analyzes cardiac CT scans using AI to deliver anatomical measurements and predict how devices will interact with specific patient anatomies. FEops also provides FEA (Finite Element Analysis) services for medical device companies to accelerate cardiovascular device R&D. The company operates as a subsidiary of Materialise following its 2024 acquisition.

Differentiator

Problem solved

Functional benefit

Brands

• FEops HEARTguide: Cloud-based structural heart procedure planning platform combining predictive simulation technology and AI for anatomical measurements in LAAO and TAVI procedures.

Products and services

• FEops HEARTguide Cloud-based structural heart procedure planning platform that combines predictive simulation technology and AI-based anatomical measurements. Analyzes cardiac CT scans to help physicians plan LAAO and TAVI procedures by predicting how transcatheter devices will interact with patient anatomy. Deployed across 466 hospitals in 38 countries with 11,461 patients modeled. Available with TAVI and LAAO indication in EU, UK, Canada, Australia, and US markets.
• FEA Services for Medtech Companies Finite Element Analysis simulation services for cardiovascular device companies to streamline R&D. Helps evaluate device design alternatives for radial strength, crimpability, fatigue risk, and deployment behavior using validated virtual human and animal patient models. Supports device development from initial design concepts through first-in-human study preparation.

Quantifiable outcome

• 15% reduction in total number of closure devices used; Twofold increase in procedural success with single device and deployment (+90 days) - PREDICT-LAA study
• +6 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• TeraReconcoreTechnology or Integration · 10 October 2023FEops partnered with TeraRecon in October 2023 to scale the commercialization of FEops HEARTguide, its digital twin solution for structural heart interventions. TeraRecon's advanced visualization and analysis capabilities complement FEops' predictive simulation technology.
• MedtroniccoreStrategic or Co-development PartnerFEops HEARTguide supports Medtronic Evolut devices (Evolut R, Evolut Pro, Evolut Pro+, Evolut FX+) for TAVI planning. Joint webinars and educational events on TAVI in bicuspid and challenging anatomies. Supports device optimization and clinical evidence generation.
• Boston ScientificcoreStrategic or Co-development PartnerFEops HEARTguide supports Boston Scientific WATCHMAN FLX and WATCHMAN FLX Pro devices for LAAO planning. Joint case discussions and webinars promoting preoperative planning using FEops simulation for Boston Scientific devices.
• AbbottcoreStrategic or Co-development PartnerFEops HEARTguide supports Abbott Amplatzer Amulet and Amulet devices for LAAO planning. Joint educational webinars and case presentations demonstrating FEops simulation for Abbott device preoperative planning.
• Venus MedtechminorStrategic or Co-development PartnerFEops supports Venus Medtech VenusA valve for TAVI interventions. China-International forums demonstrate the value of FEops HEARTguide for VenusA TAVI interventions.
• TRiCaresminorStrategic or Co-development PartnerFEops simulation technology supported TRiCares from initial design concepts to successful first-in-human Topaz TTVR procedure, providing crucial anatomical insights, preventing fatigue issues, and supporting device development.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@feops
• LinkedInlinkedin.com/company/feops

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FEops